| | | | | | | | | | | | | | | | |
| |
| Issue Date FY: 2024 ( Subtotal = $53,220,032 ) (Continued on the next page) |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA241194 | Targeting microRNAs in the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs | 001 | 5 | NIH | 4/17/2024 | $19,214 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA241194 | Targeting microRNAs in the tumor microenvironment with pHLIP conjugated next generation chemically modified PNAs | 000 | 5 | NIH | 1/8/2024 | $345,871 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS122589 | Neuronal Circuit Controlling Sleep-Promoting Ventrolateral Preoptic Neurons | 001 | 3 | NIH | 4/9/2024 | $26,242 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS122589 | Neuronal Circuit Controlling Sleep-Promoting Ventrolateral Preoptic Neurons | 000 | 3 | NIH | 1/17/2024 | $337,389 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258776 | Pan-Cancer characterization of 3?UTR somatic mutations controlling tumor immune evasion | 001 | 3 | NIH | 4/17/2024 | $28,465 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258776 | Pan-Cancer characterization of 3?UTR somatic mutations controlling tumor immune evasion | 000 | 3 | NIH | 1/23/2024 | $512,353 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL160003 | Long-Term Endothelial Effects of COVID-19 in Obesity | 000 | 3 | NIH | 2/29/2024 | $608,959 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258442 | Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma | 000 | 3 | NIH | 12/18/2023 | $352,940 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA258442 | Clinical characterization of Kidney Injury Molecule-1 (KIM-1) as a Biomarker in Renal Cell Carcinoma | 001 | 3 | NIH | 4/17/2024 | $21,229 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK126789 | Regulation of Adipose-Lymphatic Cross-talk | 000 | 4 | NIH | 5/16/2024 | $462,001 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 Brookline Ave | Boston | MA | 02215-5400 | SUFFOLK | USA | NU2GGH002212 | Strengthening Vietnam's HIV Technical Assistance Capacity | 02 | 5 | CDC | 3/1/2024 | $574,012 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 Brookline Ave | Boston | MA | 02215-5400 | SUFFOLK | USA | NU2GGH002212 | Strengthening Vietnam's HIV Technical Assistance Capacity | 02 | 5 | CDC | 3/1/2024 | $300,000 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL167383 | Thiol Isomerases and Oxidant Stress in Thrombus Formation | 000 | 1 | NIH | 5/15/2024 | $621,093 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK138503 | Integrating signals that control APOL1 gene expression and drive kidney disease | 000 | 11 | NIH | 1/19/2024 | $540,299 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS133226 | Central vs. Peripheral Mechanisms of Headache: Cortex, Thalamus, Dorsal Horn | 000 | 1 | NIH | 4/4/2024 | $419,283 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK136699 | Use of Modified mRNA for the Treatment of Diabetic Foot Ulceration | 000 | 1 | NIH | 4/19/2024 | $774,435 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01NS133187 | Targeting the FBXW7/PGC1 Pathway as a Therapeutic Strategy for Parkinson's Disease | 000 | 1 | NIH | 3/12/2024 | $665,971 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL171101 | Rechargeable Anti-thrombogenic Films for Blood Contacting Applications | 000 | 1 | NIH | 12/8/2023 | $688,880 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | F32ES036026 | Air pollution, biomarkers of exposure, and lung function in vulnerable populations | 000 | 1 | NIH | 2/9/2024 | $86,004 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K01DK139434 | Targeted mRNA Delivery to Improve Diabetic Wound Healing | 000 | 1 | NIH | 2/21/2024 | $152,236 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL161385 | Using Machine Learning to find a life saving needle in a haystack of children's emergencies | 002 | 3 | NIH | 2/13/2024 | $537,996 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23HL171855 | Mixed meal tolerance test elicited metabolite responses as novel markers of cardiometabolic risk | 000 | 1 | NIH | 2/15/2024 | $190,705 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK139288 | Mitochondrial DAMPs-driven Mechanisms of Liver Fibrosis in NASH | 000 | 1 | NIH | 3/5/2024 | $653,226 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG079864 | Brain Vulnerability in Delirium and Alzheimer?s Disease and Related Dementias: Intersection of Polygenic Risk and Inflammation | 001 | 2 | NIH | 5/2/2024 | $81,724 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG079864 | Brain Vulnerability in Delirium and Alzheimer?s Disease and Related Dementias: Intersection of Polygenic Risk and Inflammation | 000 | 2 | NIH | 11/15/2023 | $735,517 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01DK135672 | Cav1.2 in bladder physiology and pathology | 000 | 1 | NIH | 3/21/2024 | $580,586 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21AG085089 | A lab-on-a-chip device for measuring multiple biochemical and biophysical biomarkers of Alzheimer?s disease | 000 | 1 | NIH | 4/29/2024 | $236,022 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | P01AI179405 | Lupus nephritis: novel insights in the pathogenesis and treatment | 000 | 1 | NIH | 3/1/2024 | $2,247,493 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | P01AI179405 | Lupus nephritis: novel insights in the pathogenesis and treatment | 001 | 1 | NIH | 3/12/2024 | $18,225 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA276107 | Control of cancer cachexia via stimulation of resolution of inflammation | 000 | 1 | NIH | 12/27/2023 | $709,923 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R00EY032181 | Epigenomic mechanisms regulating RGC survival and axon regeneration | 000 | 4 | NIH | 1/26/2024 | $249,998 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL133870 | Proteomics of Cardiometabolic and Renal Traits in African Americans | 001 | 6 | NIH | 2/21/2024 | $569,531 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01CA263986 | Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients | 003 | 3 | NIH | 4/17/2024 | $20,244 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | U01CA263986 | Evaluation of Patient Factors and Sample Pre-Analytics on Predictive Multiplex Immunohistochemical Assays in Immuno-Oncology Patients | 002 | 3 | NIH | 12/11/2023 | $344,507 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL171121 | Novel Role Of ACTN4 in Sodium Reabsorption and Salt-Sensitive Hypertension | 000 | 1 | NIH | 12/12/2023 | $643,002 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | P30HS029762 | Massachusetts Institute for Equity-Focused Learning Health System Science (MIELHSS) | 001 | 1 | AHRQ | 1/10/2024 | $999,286 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | P30HS029762 | Massachusetts Institute for Equity-Focused Learning Health System Science (MIELHSS) | 001 | 1 | AHRQ | 1/10/2024 | -$999,286 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | P30HS029762 | Massachusetts Institute for Equity-Focused Learning Health System Science (MIELHSS) | 000 | 1 | AHRQ | 12/27/2023 | $999,286 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA271601 | Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments. | 001 | 2 | NIH | 4/17/2024 | $32,569 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01CA271601 | Understanding the cellular and functional changes in the immune tumor microenvironment of glioblastoma during progression and treatments. | 000 | 2 | NIH | 3/26/2024 | $586,256 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG082016 | Wake-sleep Circuitry in Neurodegenerative Dementias | 000 | 1 | NIH | 11/16/2023 | $900,121 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | K23AG068364 | Understanding the structural, functional, and prognostic implications of cortical excitability in Alzheimer's disease | 000 | 4 | NIH | 5/6/2024 | $165,023 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01MH131586 | FastPlex: A Fast Deep Learning Segmentation Method for Accurate Choroid Plexus Morphometry | 000 | 2 | NIH | 3/28/2024 | $560,472 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | P01AI177687 | Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination | 000 | 2 | NIH | 5/6/2024 | $1,510,625 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01HL157530 | A Multi-Dimensional Linked Registry to Identify Biological, Clinical, Health System, and Socioeconomic Risk Factors for COVID-19-Related Cardiovascular Events | 000 | 4 | NIH | 3/27/2024 | $403,673 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21MH133001 | Identification of Distinct Biotypes in Clinical High Risk for Psychosis State Using Objective Brain-Based Biomarkers | 001 | 2 | NIH | 5/13/2024 | $15,520 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R21MH133001 | Identification of Distinct Biotypes in Clinical High Risk for Psychosis State Using Objective Brain-Based Biomarkers | 000 | 2 | NIH | 1/12/2024 | $139,687 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC. | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AI148747 | An Integrated Multilevel Modeling Framework for Repertoire-Based Diagnostics | 000 | 5 | NIH | 4/11/2024 | $512,834 |
| 2024 | 2024 | BETH ISRAEL DEACONESS MEDICAL CENTER, INC | 330 BROOKLINE AVE | BOSTON | MA | 02215-5400 | SUFFOLK | USA | R01AG082093 | Non-coding RNAs in resilience to Alzheimer?s Disease | 001 | 2 | NIH | 2/26/2024 | $759,851 |
|